Health Canada Grants Device License for iCAD’s ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer...